BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jeong H, Shin J, Jeong JH, Kim KP, Hong SM, Kim YI, Ryu JS, Ryoo BY, Yoo C. Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study. ESMO Open 2021;6:100119. [PMID: 33901869 DOI: 10.1016/j.esmoop.2021.100119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Kong G, Boehm E, Prall O, Murray WK, Tothill RW, Michael M. Integrating Functional Imaging and Molecular Profiling for Optimal Treatment Selection in Neuroendocrine Neoplasms (NEN). Curr Oncol Rep 2023. [PMID: 36826704 DOI: 10.1007/s11912-023-01381-w] [Reference Citation Analysis]
2 Donadio MD, Brito ÂB, Riechelmann RP. A systematic review of therapeutic strategies in gastroenteropancreatic grade 3 neuroendocrine tumors. Ther Adv Med Oncol 2023;15:17588359231156218. [PMID: 36950274 DOI: 10.1177/17588359231156218] [Reference Citation Analysis]
3 Robinson MD, Livesey D, Hubner RA, Valle JW, McNamara MG. Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review. Ther Adv Med Oncol 2023;15:17588359231156870. [PMID: 36872945 DOI: 10.1177/17588359231156870] [Reference Citation Analysis]
4 Arrivi G, Verrico M, Roberto M, Barchiesi G, Faggiano A, Marchetti P, Mazzuca F, Tomao S. Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis. Cancer Manag Res 2022;14:3507-23. [PMID: 36575665 DOI: 10.2147/CMAR.S372776] [Reference Citation Analysis]
5 Agarwal P, Mohamed A. Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues. Curr Treat Options Oncol 2022. [PMID: 35939200 DOI: 10.1007/s11864-022-00998-6] [Reference Citation Analysis]
6 Dogan I, Tastekin D, Karabulut S, Sakar B. Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors. J Dig Dis 2022;23:493-9. [PMID: 36081250 DOI: 10.1111/1751-2980.13123] [Reference Citation Analysis]
7 Papamichail M, Pizanias M, Heaton ND. Minimizing the risk of small-for-size syndrome after liver surgery. Hepatobiliary Pancreat Dis Int 2022;21:113-33. [PMID: 34961675 DOI: 10.1016/j.hbpd.2021.12.005] [Reference Citation Analysis]
8 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Al-toubah T, Morse B, Strosberg J. Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors. Current Oncology 2022;29:510-5. [DOI: 10.3390/curroncol29020046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lima Cavalcanti ID. Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer. Chemotherapy Protocols and Infusion Sequence 2022. [DOI: 10.1007/978-3-031-10839-6_5] [Reference Citation Analysis]
11 Xu JX, Wu DH, Ying LW, Hu HG. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification. World J Gastroenterol 2021; 27(47): 8123-8137 [DOI: 10.3748/wjg.v27.i47.8123] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Auernhammer CJ, Böck S, Westphalen CB, Beyer L, Spitzweg C. Medikamentöse Systemtherapie bei Neuroendokrinen Neoplasien des GastroEnteropankreatischen Systems. Der Nuklearmediziner 2021;44:326-333. [DOI: 10.1055/a-1556-8264] [Reference Citation Analysis]
13 Das S, Al-Toubah T, Strosberg J. Chemotherapy in Neuroendocrine Tumors. Cancers (Basel) 2021;13:4872. [PMID: 34638356 DOI: 10.3390/cancers13194872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Zhou S, Jiang S, Chen W, Yin H, Dong L, Zhao H, Han S, He X. Biliary Neuroendocrine Neoplasms: Analysis of Prognostic Factors and Development and Validation of a Nomogram. Front Oncol 2021;11:654439. [PMID: 34350109 DOI: 10.3389/fonc.2021.654439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]